Transformative vascular implants
Addressing major life-threatening diseases, backed by Nobel-winning science
Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue.
The natural creation of living and long-lasting vessels reduces the risk of thrombosis, stenosis, calcification and infection which are often the root cause of failure.
These groundbreaking implants, based on our proprietary Endogenous Tissue Restoration (ETR) based platform, are transforming the treatment of major life-threatening diseases.
Xeltis’ ETR technology is driven by Nobel prize-winning breakthroughs in polymer technology.
The ambition at Xeltis is to improve standards of care for millions of patients who undergo vascular surgery every year, including hemodialysis access and coronary arterial bypass surgery.
Other potential applications for RestoreXTM, our ETR platform, include pulmonary heart valves and other vascular indications such as peripheral arterial disease.
Xeltis aims to meet the needs of patients and healthcare providers by providing self-healing, non-immunogenic implants that remain open, with a low risk of infection and reduced need for surgical reintervention.
Xeltis is looking to break the cycle of surgery, complications and reinterventions in current vascular and valve replacement options by providing transformational treatment options for patients worldwide.
Visit our Patients page for an overview of our ongoing clinical trials.
Xeltis is an international business with its roots in the Netherlands and clinical operations throughout Europe and the US. We are a passionate and driven team, with expertise from world-renowned universities and innovative life science companies and backed by high-quality advisors and investors.